A Tulane Spinout's $1.25 Million Bet on Beating Superbugs Before They Beat Us

Informuta cashed a $1.25 million check from the National Science Foundation this month, and it did not come easy. The New Orleans biotech, founded three years ago as a Tulane University spinout, has been awarded a Small Business Innovation Research Phase II grant, one of roughly 80 such awards NSF hands out nationwide each year out of a $200 million annual pool for startups, according to the company's September 2026 announcement. That scarcity is the point. The company still has to prove the technology works at scale in hospitals. It is federal money going to a company that already proved something works in Phase I and now has to prove it works at scale, inside hospitals, with real patients.

What Informuta is building matters more than the dollar figure. Current antibiotic tests tell a doctor what works today. They cannot tell a doctor whether the bacteria sitting in a patient's bloodstream will mutate into something resistant three days into treatment. Informuta's platform, built on whole-genome sequencing and predictive genomic biomarkers layered with artificial intelligence, is trying to answer that question before it becomes a crisis. Antibiotic resistance is one of those slow-moving public health threats that does not generate headlines until a hospital ward runs out of options. A company in New Orleans is trying to get ahead of it, and the federal government just put real money behind the bet.

The grant funds two years of work running through August 2028, with CEO and co-founder Kalen Hall as principal investigator. Hall put the moment in plain terms: "Phase I asked whether this biology could be turned into a predictive technology. Phase II asks the harder and more important question: can we make that prediction reliably inside real hospital workflows and use it to help clinicians make better treatment decisions?" That is the right question, and it is the expensive one. Turning a promising lab result into something a hospital microbiology department will actually trust and use is where most biotech companies stall out. Informuta has real work ahead to prove the technology in hospitals. It is partnering with the University of Pittsburgh Medical Center, which has worked with the company since Phase I, and adding the University of California, Irvine, to validate its models against clinical bacterial isolates. It has also run earlier clinical validation work with Ochsner Health here in Louisiana, comparing its predictions against real-world patient outcomes.

The company operates out of the New Orleans BioInnovation Center, where it opened its lab in September 2025 and where it won the 2024 BioChallenge pitch competition. It has drawn early capital from a genuinely Louisiana bench of investors: the New Orleans BioFund, Tulane Ventures, 1834 Ventures, Boot64 Ventures and Flamingo Funders. That is a homegrown funding stack, not out-of-state private equity parachuting in to strip a company for parts. NOBIC executive director Kris Khalil made the underlying point about what Phase II actually signals: "NSF Phase II awards go to companies that delivered on their Phase I work, and Kalen and her team delivered." Khalil also flagged the next hurdles, CLIA certification and CAP accreditation, the regulatory gauntlet every clinical lab has to clear before its results mean anything to a hospital system. Informuta is working through it with support from BioDistrict New Orleans and Louisiana Economic Development, the kind of state-level scaffolding that turns a university lab project into an actual employer.

This is the version of economic development I want to see more of coming out of Louisiana: not a subsidy chase for a warehouse or a call center, but a company built on Tulane research, staffed with people who have real scientific credentials, going after a problem, antibiotic resistance, that costs the American healthcare system billions and puts patients at risk every year. Informuta has beefed up its leadership accordingly, bringing on Ryan Shields as chief medical officer, Ayesha Khan as vice president of clinical microbiology, and Barbara Zehentner as lab director, the kind of hires you make when you are done pitching investors and about to start running clinical trials for real. New Orleans has spent years trying to build a biotech identity beyond its energy and shipping base. A company using AI to predict how bacteria evolve, funded by a competitive federal science grant, tested in partnership with two major academic medical systems, is exactly the kind of proof point that argument needed. The next milestone to watch is whether Informuta clears CLIA and CAP in time to start generating the prospective clinical evidence its NSF grant is paying for.